Venus Remedies Ltd Hits All-Time High of Rs 1,702.95 as Momentum Builds Across Timeframes

Price Action and Volatility

The stock demonstrated significant intraday volatility, swinging between a low of Rs 1,561.05 and the record high of Rs 1,702.95, reflecting a 43.44% intraday volatility based on weighted average price. Despite this, Venus Remedies Ltd closed with a 4.99% gain, outperforming its sector by 3.3%. The stock is trading comfortably above all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day, signalling a robust technical backdrop. The bullish alignment of MACD, Bollinger Bands, KST, Dow Theory, and OBV across weekly and monthly timeframes further supports the prevailing uptrend, although the monthly RSI shows some bearish divergence, hinting at potential short-term consolidation.Could this volatility herald a pause or a continuation of the rally?

Exceptional Multi-Period Performance

The stock’s performance over various time horizons is eye-catching. Over the past year, Venus Remedies Ltd has delivered a staggering 299.71% return, vastly outperforming the Sensex’s 10.46% decline. Extending the view further, the three-year return stands at an extraordinary 664.91%, dwarfing the BSE500’s 17.10% gain. Even over a decade, the stock has appreciated by nearly 1,949%, a testament to its long-term growth trajectory. This scale of outperformance raises questions about sustainability and whether the stock’s premium valuation is justified by fundamentals.At these valuations, should you be booking profits on Venus Remedies Ltd or can the company grow into this premium?

Financial Trend and Profitability

The recent quarterly results underpin the stock’s strong price action. Net sales for the quarter reached Rs 259.40 crores, growing at 33.05% year-on-year, while profit before tax excluding other income surged 133.36% to Rs 56.66 crores. Operating profit margins have expanded to 24.45%, with PBDIT hitting a record Rs 63.42 crores. The company reported its highest quarterly PAT of Rs 47.50 crores and EPS of Rs 35.53, reflecting a robust earnings trajectory. These figures align with a positive short-term financial trend, supported by a high ROCE of 19.85% for the half-year period.Does this earnings momentum justify the current valuation premium?

Valuation Metrics and Premium

Despite the strong earnings growth, Venus Remedies Ltd trades at a price-to-earnings ratio of 21x, which is moderate but accompanied by a price-to-book value of 3.3x, indicating a premium relative to book value. The EV/EBITDA multiple stands at 14.24x, and the EV/EBIT ratio is 17.24x, both suggesting stretched valuations compared to typical industry averages. The PEG ratio is notably low at 0.12x, reflecting the rapid earnings growth relative to price. However, the company’s return on equity (ROE) and return on capital employed (ROCE) averages over five years are relatively modest at 8.61% and 9.53%, respectively, which may temper enthusiasm for the valuation.Is this valuation premium sustainable given the company’s capital efficiency metrics?

Quality and Balance Sheet Strength

The company’s quality metrics present a mixed but generally positive picture. It is a net cash company with an average net debt to equity ratio of -0.14, and an excellent capital structure with low debt-to-EBITDA of 0.54. Interest coverage is very strong at 50.94x, and there is no promoter share pledging, which supports financial stability. However, the average ROCE and ROE over five years are on the weaker side, suggesting that while growth has been strong, capital utilisation could improve. Institutional investors hold a modest 4% stake, having increased their position by 0.72% in the previous quarter, signalling some confidence from more sophisticated market participants.What does the balance between strong growth and moderate returns on capital imply for long-term investors?

Technical Indicators and Market Sentiment

Technically, the stock is in a bullish phase since 12 Mar 2026, with all major indicators such as MACD, Bollinger Bands, KST, Dow Theory, and OBV confirming the uptrend on both weekly and monthly charts. The stock’s delivery volumes have surged, with a 184% increase in 1-day delivery compared to the 5-day average, indicating strong participation. Immediate support is well below current levels at Rs 417.65, the 52-week low, while resistance levels have been decisively breached. The only cautionary note is the monthly RSI showing bearish signals, which could suggest some near-term profit-taking or consolidation.How might these technical signals influence the stock’s trajectory in the coming weeks?

Balancing the Bull and Bear Cases

The rally in Venus Remedies Ltd is supported by strong earnings growth, a clean balance sheet, and bullish technical indicators. The company’s net sales and profitability have expanded impressively, with positive results for six consecutive quarters. However, the valuation multiples, particularly the price-to-book ratio and EV/EBITDA, suggest that the stock is trading at a premium relative to its historical and peer benchmarks. The moderate returns on capital employed and equity raise questions about the efficiency of capital deployment despite rapid growth. This disconnect between price momentum and fundamental metrics means that while the momentum appears supportive, the data suggests caution may be warranted.Should you buy, sell, or hold? With momentum and valuations pulling in opposite directions, no single data point tells the full story — see the complete multi-factor analysis of Venus Remedies Ltd to find out.

Key Data at a Glance

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today